Please login to the form below

Not currently logged in
Email:
Password:

EMA/HMA set drug application guidance

The European Medicines Agency and Heads of Medicines Agencies have released draft guidance detailing what information included in marketing authorisation applications for drugs can be released

The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) have released draft guidance detailing what information included in marketing authorisation applications companies file for new drugs can be released.

The guidance defines what is commercially confidential information and personal data, with this information to remain protected.

The agencies said the measures are to make application dossiers 'more transparent' and to address requests from members of the public in a more efficient manner. Non-protected information is to become available once a marketing authoristation has been granted.

A consultation period for the draft measures is currently ongoing, with deadline for comments of September 1, 2011.

The EMA said: "The Agency and the HMA are particularly interested in receiving comments on the criteria for the release or protection of personal data, whether contractual arrangements between companies need to be maintained as confidential, and how to address the personal security of individuals involved in studies using animals."

Stakeholders are also invited to share ideas on how to make requests for information easier.

Following the consultation period, the EMA and the HMA will assess all comments received before completing a final version of the guidance document.

The EMA has the full draft guidance available for download.

Comments should be sent to hma-ematransparencyconsultation@ema.europa.eu

2nd June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....